{
    "clinical_study": {
        "@rank": "141310", 
        "acronym": "DIPE", 
        "arm_group": [
            {
                "arm_group_label": "DBD arm", 
                "arm_group_type": "Experimental", 
                "description": "Epirubicin: 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 DBD: one dose of medicine twice per day, orally OR; Docetaxel: 75mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 DBD: one dose of medicine twice per day, orally"
            }, 
            {
                "arm_group_label": "EC/TC", 
                "arm_group_type": "Other", 
                "description": "Epirubicin: 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 OR; Docetaxel: 75mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate EC/TC (epirubicin and cyclophosphomide or docetaxel and cyclophosphomide) with\n      EC/TC plus DBD (Danggui Buxue Decoction)  in adjuvant treatment of breast cancer patients.\n      The aim is to evaluate whether DBD can decrease the incidence of grade 3/4 neutropenia\n      induced by EC/TC regimen during chemotherapy."
        }, 
        "brief_title": "Study of Danggui Buxue Decoction in Preventing Neutropenia", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Grade 3/4 Neutropenia", 
            "Febrile Neutropenia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fever", 
                "Neutropenia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Women aged \u226518 years and < 70 years; Histologically confirmed invasive breast cancer by\n        core needle biopsy, suggested to receive EC/TC regiments for adjuvant chemotherapy by MDT;\n        Leukocyte \u2265 3*109/L; Neutrophil \u2265 1.5*109/L; PLT \u2265 100*109/L; Serum AST/SGOT or ALT/AGPT \u2264\n        2.5 times of upper limit of normal (UNL) range Serum creatinine/BUN \u2264 upper limit of\n        normal (UNL) range; No dysphagia, be able to take the  Danggui Buxue Decoction(DBD)\n        Written informed consent according to the local ethics committee requirements. Has ECOG\n        Performance Score 0-1;\n\n        Exclusion Criteria:\n\n        Metastatic breast cancer; Family history of endometrial cancer or any other kind of\n        gynecologic cancer; Patients with severe co-morbidity that indicate intolerant to adjuvant\n        chemotherapy; patients with psychiatric disorder or other diseases leading to incompliance\n        to the therapy; Known severe hypersensitivity to any drugs in this study; Prior adjuvant\n        chemotherapy of any kind cancer; Hematologic disorders relative to aplasia"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005783", 
            "org_study_id": "DIPE"
        }, 
        "intervention": [
            {
                "arm_group_label": "DBD arm", 
                "description": "DBD:one dose of medicine twice per day, orally", 
                "intervention_name": "DBD", 
                "intervention_type": "Drug", 
                "other_name": "Danggui Buxue Decoction"
            }, 
            {
                "arm_group_label": [
                    "DBD arm", 
                    "EC/TC"
                ], 
                "description": "Epirubicin:90mg/m2, d1, q3w*4", 
                "intervention_name": "Epirubicin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "DBD arm", 
                    "EC/TC"
                ], 
                "description": "Cyclophosphamide:600mg/m2, d1, q3w*4", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "DBD arm", 
                    "EC/TC"
                ], 
                "description": "Docetaxel:75mg/m2, d1, q3w*4", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Docetaxel", 
                "Epirubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "incidence of grade 3/4 neutropenia", 
            "incidence of febrile neutropenia", 
            "time to neutropenia recovery", 
            "safety"
        ], 
        "lastchanged_date": "December 9, 2013", 
        "location": {
            "contact": {
                "email": "chenxiaosong0156@hotmail.com", 
                "last_name": "Xiaosong Chen, Dr.", 
                "phone": "0086-64370045", 
                "phone_ext": "602205"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200025"
                }, 
                "name": "Ruijin Hospital, Shanghai Jiaotong University School of Medicine"
            }, 
            "investigator": {
                "last_name": "Kunwei Shen, Pro.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Adjuvant Treatment of EC/TC Versus EC/TC Plus Danggui Buxue Decoction in Breast Cancer\uff1aA Prospective, Randomized Trial", 
        "overall_contact": {
            "email": "chenxiaosong0156@hotmail.com", 
            "last_name": "Xiaosong Chen, Dr", 
            "phone": "64370045", 
            "phone_ext": "602205"
        }, 
        "overall_official": {
            "affiliation": "Ruijin Hospital, Shanghai Jiaotong University School of Medicine", 
            "last_name": "Kunwei Shen, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare the incidence of grade 3/4 neutropenia between EC/TC arm and EC/TC plus DBD arm in breast cancer adjuvant chemotherapy.", 
            "measure": "incidence of grade 3/4 neutropenia", 
            "safety_issue": "Yes", 
            "time_frame": "3 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005783"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Jiao Tong University School of Medicine", 
            "investigator_full_name": "Kunwei Shen", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare the times of grade 3/4 neutropenia per cycle of chemotherapy between EC/TC arm and EC/TC plus DBD arm in breast cancer adjuvant chemotherapy.", 
                "measure": "times of grade 3/4 neutropenia per cycle of chemotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "3 weeks"
            }, 
            {
                "description": "to compare incidence of febrile neutropenia between EC/TC arm and EC/TC plus DBD arm in breast cancer adjuvant chemotherapy.", 
                "measure": "incidence of febrile neutropenia", 
                "safety_issue": "Yes", 
                "time_frame": "3 weeks"
            }, 
            {
                "description": "to compare the time to neutropenia recovery between EC/TC arm and EC/TC plus DBD arm in breast cancer adjuvant chemotherapy.", 
                "measure": "the time to neutropenia recovery", 
                "safety_issue": "Yes", 
                "time_frame": "2 months"
            }
        ], 
        "source": "Shanghai Jiao Tong University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai Jiao Tong University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}